These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 7022769)

  • 1. The interaction of spironolactone and digoxin: a review and evaluation.
    Thomas RW; Maddox RR
    Ther Drug Monit; 1981; 3(2):117-20. PubMed ID: 7022769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Digoxin-quinidine-spironolactone interaction.
    Fenster PE; Hager WD; Goodman MM
    Clin Pharmacol Ther; 1984 Jul; 36(1):70-3. PubMed ID: 6734052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spironolactone interference with digoxin radioimmunoassay in cirrhotic patients.
    DiPiro JT; Cote JR; DiPiro CR; Bustrack JA
    Am J Hosp Pharm; 1980 Nov; 37(11):1518-21. PubMed ID: 7211855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interactions between digoxin and potassium-sparing diuretics.
    Waldorff S; Hansen PB; Egeblad H; Berning J; Buch J; Kjaergård H; Steiness E
    Clin Pharmacol Ther; 1983 Apr; 33(4):418-23. PubMed ID: 6831820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interference of spironolactone metabolites in a digoxin radioimmunoassay.
    Crothers DC
    Ther Drug Monit; 1989; 11(1):113-4. PubMed ID: 2911846
    [No Abstract]   [Full Text] [Related]  

  • 6. Spironolactone-induced changes in digoxin kinetics.
    Waldorff S; Andersen JD; Heebøll-Nielsen N; Nielsen OG; Moltke E; Sørensen U; Steiness E
    Clin Pharmacol Ther; 1978 Aug; 24(2):162-7. PubMed ID: 679595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The effects of diphenylhydantoin and spironolactone on the digoxin pharmacokinetics in the rabbit (author's transl)].
    Tato F; Pérez Fontán J; Lloveres J
    Arch Farmacol Toxicol; 1980 Aug; 6(2):151-60. PubMed ID: 7469497
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of spironolactone, potassium canrenoate and their common metabolite canrenone on serum digoxin measurement by digoxin III, a new digoxin immunoassay.
    Dasgupta A; Tso G; Wells A
    Ther Drug Monit; 2008 Dec; 30(6):744-7. PubMed ID: 18824952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postulated effects of alterations in Na+,K+-ATPase on the pharmacokinetics and pharmacodynamics of digoxin.
    Rosenbloom D; Craven MA
    Clin Pharm; 1983; 2(2):168-73. PubMed ID: 6309471
    [No Abstract]   [Full Text] [Related]  

  • 10. The effect of oral spironolactone and intravenous canrenoate-K on the digoxin radioimmunoassay.
    Lichey J; Schröder R; Rietbrock N
    Int J Clin Pharmacol Biopharm; 1977 Dec; 15(12):557-9. PubMed ID: 598949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition by basic drugs of digoxin secretion into human bile.
    Hedman A
    Eur J Clin Pharmacol; 1992; 42(4):457-9. PubMed ID: 1516611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction between digoxin and commonly coadministered drugs in children.
    Koren G
    Pediatrics; 1985 Jun; 75(6):1032-7. PubMed ID: 4000777
    [No Abstract]   [Full Text] [Related]  

  • 13. Spironolactone-associated digoxin radioimmunoassay interference.
    Silber B; Sheiner LB; Powers JL; Winter ME; Sadée W
    Clin Chem; 1979 Jan; 25(1):48-50. PubMed ID: 761378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abbott ARCHITECT clinical chemistry and immunoassay systems: digoxin assays are free of interferences from spironolactone, potassium canrenoate, and their common metabolite canrenone.
    DeFrance A; Armbruster D; Petty D; Cooper KC; Dasgupta A
    Ther Drug Monit; 2011 Feb; 33(1):128-31. PubMed ID: 21079546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spironolactone as a source of interference in commercial digoxin immunoassays.
    Morris RG; Lagnado PY; Lehmann DR; Frewin DB; Glistak ML; Burnet RB
    Ther Drug Monit; 1987 Jun; 9(2):208-11. PubMed ID: 3617160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Digoxin assays: frequent, substantial, and potentially dangerous interference by spironolactone, canrenone, and other steroids.
    Steimer W; Müller C; Eber B
    Clin Chem; 2002 Mar; 48(3):507-16. PubMed ID: 11861441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of spironolactone on the renal clearance of digoxin in dogs.
    O'Brien MS; Salamone LF; Gibson TP
    J Pharmacol Exp Ther; 1985 Jul; 234(1):190-4. PubMed ID: 4009501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cross reactivity of digitoxin and spironolactone in two radioimmunoassays for serum digoxin.
    Müller H; Bräuer H; Resch B
    Clin Chem; 1978 Apr; 24(4):706-9. PubMed ID: 639280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of spironolactone and its metabolite canrenone on serum digoxin assays.
    Foukaridis GN
    Ther Drug Monit; 1990 Jan; 12(1):82-4. PubMed ID: 2305425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reassessment of cross-reactivity of spironolactone metabolites with four digoxin immunoassays.
    Pleasants RA; Williams DM; Porter RS; Gadsden RH
    Ther Drug Monit; 1989; 11(2):200-4. PubMed ID: 2655203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.